Skip to main content

Overcoming Resistance To Egfr Inhibitors In Egfr Mutant Nsclc

Download Overcoming Resistance To Egfr Inhibitors In Egfr Mutant Nsclc Full eBooks in PDF, EPUB, and kindle. Overcoming Resistance To Egfr Inhibitors In Egfr Mutant Nsclc is one my favorite book and give us some inspiration, very enjoy to read. you could read this book anywhere anytime directly from your device.

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC Book
Author : Anthony Faber
Publisher : Academic Press
Release : 2021-03-15
ISBN : 9780128228333
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC, Volume 17 presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer. Presents historical context on how NSCLC and SCLC has been treated, with an emphasis on NSCLC and how the concept of EGFR inhibitors has been implemented Discusses critical resistant mechanisms seen in the clinic to 1st, 2nd and 3rd generation EGFR inhibitors Encompasses the current state of affairs in clinical trials to address resistance

Overcoming Drug Resistance in Gynecologic Cancers

Overcoming Drug Resistance in Gynecologic Cancers Book
Author : Anonim
Publisher : Academic Press
Release : 2021-08-11
ISBN : 0128243007
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. Provides a comprehensive resource with all the details needed for readers to understand and follow information Encompasses schematics, diagrams and flow charts in all chapters to help readers easily follow critical information Presents tables and figures especially developed to summarize the information with appropriate statistical rigor and to show details of clinical specimens such as pathological, radiological characteristics, and/or laboratory biomarkers

Epigenetic Regulation in Overcoming Chemoresistance

Epigenetic Regulation in Overcoming Chemoresistance Book
Author : Chunfu Wu,Lihui Wang
Publisher : Academic Press
Release : 2021-06-26
ISBN : 012823685X
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Epigenetic Regulation in Overcoming Chemoresistance, Volume 19, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally, recent and future developments of the field of epigenetic regulation are explored. This is a valuable resource for cancer researchers, clinicians, graduate students and several members of biomedical field who are interested in learning about epigenetic regulation methods to reverse chemo-resistance in cancers. Presents detailed diagrams of the mechanisms of epigenetic regulation for easy consult Encompasses multiple clinical trial summary diagrams to help readers quickly and clearly get information from clinical trials Provides future perspectives in each section to inspire readers to use epigenetic regulation to overcome chemo-resistance

Third Generation EGFR Inhibitors

Third Generation EGFR Inhibitors Book
Author : Harun M. Patel,Rahul Pawara,S. J. Surana
Publisher : Elsevier
Release : 2019-03-15
ISBN : 9780081026618
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

EGFR inhibitors are useful tools in cancer therapeutics, but resistance to the first generations have significantly increased, meaning a new generation of improved inhibitors are needed with better efficacy and lower toxicity. Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the next generation of drugs. Beginning with an introduction to EGFR inhibitors and a review of inhibitors currently approved or in clinical trials, the book goes on to discuss current approaches in the development of both covalent irreversible and covalent reversible EGFR Inhibitors. Mechanisms of resistance to third generation inhibitors, and discovery of fourth generation allosteric C797S inhibitors are then explored before a discussion of potential future trends. Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems is a guide for medicinal chemists, drug developer, and researchers investigating cancer therapeutics, supporting them in the design and development of improved analogues to overcome the problems of resistance and toxicity associated with third generation EGFR inhibitors. Includes full synthetic schemes of all approved and in-trial third generation inhibitors Highlights the emergence of fourth generation EGFR inhibitors and looks at how they may be able to overcome the constraints of third generation compounds Provides a structural correlation of third and fourth generation EGFR inhibitors and reviews both their design strategies and typical anticancer activity

Glioblastoma Resistance to Chemotherapy Molecular Mechanisms and Innovative Reversal Strategies

Glioblastoma Resistance to Chemotherapy  Molecular Mechanisms and Innovative Reversal Strategies Book
Author : Ramasamy Paulmurugan,Tarik F. Massoud
Publisher : Academic Press
Release : 2021-06-25
ISBN : 0128215682
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists, neuro-oncologists and other members of the biomedical field. Glioblastoma (GBM) is the most invasive and malignant primary brain tumor in humans with poor survival after diagnosis, therefore it is imperative that molecular and cellular mechanisms behind therapy resistant GBM cells, as well as the therapeutic strategies available to counter the resistance are comprehensively understood. Provides comprehensive, core knowledge related to the entire discipline of glioblastoma chemoresistance, from its many etiological mechanisms, to specific strategies to reverse resistance Presents current information from an international team of experts on the basic science, pre-clinical research, and clinical management of glioblastoma chemoresistance Discusses molecular and cellular mechanisms behind therapy resistant glioblastoma cells, as well as the therapeutic strategies available to counter this resistance

Current Applications for Overcoming Resistance to Targeted Therapies

Current Applications for Overcoming Resistance to Targeted Therapies Book
Author : Myron R. Szewczuk,Bessi Qorri,Manpreet Sambi
Publisher : Springer
Release : 2019-07-15
ISBN : 303021477X
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.

Acquired Resistance to Targeted Therapy in EGFR mutant Lung Adenocarcinoma

Acquired Resistance to Targeted Therapy in EGFR mutant Lung Adenocarcinoma Book
Author : Caroline Amalia Nebhan
Publisher : Unknown
Release : 2014
ISBN : 0987650XXX
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Download Acquired Resistance to Targeted Therapy in EGFR mutant Lung Adenocarcinoma book written by Caroline Amalia Nebhan, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy

Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy Book
Author : Anonim
Publisher : Academic Press
Release : 2022-01-14
ISBN : 0323905560
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 19 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti-neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds—molecules that inhibit the growth of vessels inside a tumor—together with antineoplastic drugs in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients. In addition, the book discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin and brain and circulating tumors. It is a valuable resource for cancer researchers, clinicians and members of the biomedical field who wants to be up-to-date on the most recent and promising developments in the field. Provides the most updated reviews on anti-angiogenic drugs as chemosensitizers by leaders in the field Encompasses summarized tables and schematic diagrams in each chapter to give a clear overview on recent findings in a didactic manner Brings not only relevant information of current research but also new ideas and suggestions for further investigations to help advance the field

New Targeting in The Reversal of Resistant Glioblastomas

New Targeting in The Reversal of Resistant Glioblastomas Book
Author : Ali Syed Arbab
Publisher : Academic Press
Release : 2021-03-05
ISBN : 0128232765
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field. Explains the effect of bone marrow derived cells on the development of resistance to clinically practiced therapies Provides information on the availability of alternate therapies for recurrent glioblastoma when standard practices have failed Discusses targeting tumor microenvironment using available FDA approved drugs as an alternative treatment strategy for glioblastoma

Biotargets of Cancer in Current Clinical Practice

Biotargets of Cancer in Current Clinical Practice Book
Author : Mauro Bologna
Publisher : Springer Science & Business Media
Release : 2012-04-05
ISBN : 161779614X
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Biotargets of Cancer in Current Clinical Practice presents an updated and reasoned review of the current status of knowledge concerning the major cancer types with a special focus on the current biomarkers, genes involved and the potential future targets of innovative therapies. The volume includes for each major cancer type, a comprehensive although concise discussion of epidemiology, affirmed and innovative biomarkers for diagnosis, and descriptions of the relevant genes for prognosis and (individualized) therapy through biotarget-specific new molecular treatments, with the latest information on the validation status of each novel biomarker. Individual chapters are dedicated to the major cancer types, plus a special chapter on metastasis. The present debate on patentability of genetic information applied to diagnostics and therapeutics of cancer is also discussed.

Third Generation EGFR Inhibitors

Third Generation EGFR Inhibitors Book
Author : Harun M. Patel,Rahul Pawara,Sanjay J. Surana
Publisher : Elsevier
Release : 2018-11-27
ISBN : 0081026625
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the next generation of drugs. Beginning with an introduction to EGFR inhibitors and a review of inhibitors currently approved or in clinical trials, the book goes on to discuss current approaches in the development of both covalent irreversible and covalent reversible EGFR Inhibitors. In addition, mechanisms of resistance to third generation inhibitors, and discovery of fourth generation allosteric C797S inhibitors are explored before a discussion of potential future trends. This comprehensive coverage of the design and development of improved analogues to overcome the problems of resistance and toxicity associated with third generation EGFR inhibitors makes Third Generation EGFR Inhibitors a crucial resource for medicinal chemists, drug developers, and researchers investigating cancer therapeutics. Includes full synthetic schemes of all approved and in-trial third generation inhibitors Highlights the emergence of fourth generation EGFR inhibitors and the possibilities of them overcoming constraints of third generation compounds Provides a structural correlation of third and fourth generation EGFR inhibitors, reviewing both their design strategies and typical anticancer activity

Textbook of Personalized Medicine

Textbook of Personalized Medicine Book
Author : Kewal K. Jain
Publisher : Humana Press
Release : 2015-03-17
ISBN : 1493925539
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Advances in the technology used in personalized medicine and increased applications for clinical use have created a need for this expansion and revision of Kewal K. Jain’s Textbook of Personalized Medicine. As the first definitive work on this topic, this book reviews the fundamentals and development of personalized medicine and subsequent adoptions of the concepts by the biopharmaceutical industry and the medical profession. It also discusses examples of applications in key therapeutic areas, as well as ethical and regulatory issues, providing a concise and comprehensive source of reference for those involved in healthcare management, planning and politics. Algorithms are included as a guide to those involved in the management of important diseases where decision-making is involved due to the multiple choices available. Textbook of Personalized Medicine, Second Edition will serve as a convenient source of information for physicians, scientists, decision makers in the biopharmaceutical and healthcare industries and interested members of the public.

Lung Cancer and Personalized Medicine Novel Therapies and Clinical Management

Lung Cancer and Personalized Medicine  Novel Therapies and Clinical Management Book
Author : Aamir Ahmad,Shirish M. Gadgeel
Publisher : Springer
Release : 2015-12-24
ISBN : 3319249320
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

This, the second of two volumes on personalized medicine in lung cancer, touches upon the recent progress in targeted drug development based on genomics; emerging biomarkers and therapeutic targets such as EMT, cancer stem cells, and the tumor microenvironment; current personalized clinical management and radiation therapy for lung cancers; and the promise of epigenetics and next-generation sequencing for the advancements towards personalized therapy of lung cancer patients. With chapters on state-of-the-art therapies and technologies written by leading experts working to develop novel companion diagnosis tools for the personalized treatment of lung cancer patients, this volume brings readers up-to-date by presenting the current knowledge on the efforts to make personalized management of lung cancer patients a reality.

Novel Small Molecule Agents in Overcoming Multidrug Resistance in Cancers

Novel Small Molecule Agents in Overcoming Multidrug Resistance in Cancers Book
Author : Qingbin Cui,Yingfang Fan,Qianxiong Zhou,Cong Wang,Leli Zeng
Publisher : Frontiers Media SA
Release : 2022-05-30
ISBN : 2889762351
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Download Novel Small Molecule Agents in Overcoming Multidrug Resistance in Cancers book written by Qingbin Cui,Yingfang Fan,Qianxiong Zhou,Cong Wang,Leli Zeng, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

AACR 2016 Abstracts 1 2696

AACR 2016  Abstracts 1 2696 Book
Author : American Association for Cancer Research (AACR)
Publisher : CTI Meeting Technology
Release : 2016-03-28
ISBN : 0987650XXX
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

The AACR Annual Meeting is a must-attend event for cancer researchers and the broader cancer community. This year's theme, "Delivering Cures Through Cancer Science," reinforces the inextricable link between research and advances in patient care. The theme will be evident throughout the meeting as the latest, most exciting discoveries are presented in every area of cancer research. There will be a number of presentations that include exciting new data from cutting-edge clinical trials as well as companion presentations that spotlight the science behind the trials and implications for delivering improved care to patients. This book contains abstracts 1-2696 presented on April 17-18, 2016, at the AACR Annual Meeting.

Targeted Therapies in Lung Cancer Management Strategies for Nurses and Practitioners

Targeted Therapies in Lung Cancer  Management Strategies for Nurses and Practitioners Book
Author : Marianne Davies,Beth Eaby-Sandy
Publisher : Springer
Release : 2019-07-16
ISBN : 3030165507
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

This book aims to educate nurses and advanced practice providers (APP’s) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP’s are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents. Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers. To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP’s with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations. With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.

Exploitation and Mechanistic Validation of Drug combination Strategies to Overcome EGFR inhibitor Resistance in NSCLC Cells

Exploitation and Mechanistic Validation of Drug combination Strategies to Overcome EGFR inhibitor Resistance in NSCLC Cells Book
Author : Yu-Chieh Wang
Publisher : Unknown
Release : 2008
ISBN : 0987650XXX
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Abstract: Pre-existing and acquired resistance to epidermal growth factor receptor (EGFR) inhibitors limits their clinical usefulness in patients with advanced non-small cell lung cancer (NSCLC). In this dissertation research work, the in vitro/in vivo efficacy and mechanisms of the combination of gefitinib or erlotinib with OSU-03012, a celecoxib-derived antitumor agent, to overcome EGFR inhibitor-resistance in three NSCLC cell lines, H1155, H23, and A549, are characterized. The OSU-03012/EGFR inhibitor combination induced pronounced apoptosis in H1155 and H23 cells, but not in A549 cells, suggesting a correlation between drug sensitivity and basal phospho-Akt levels independently of EGFR expression status. Evidence indicates that this combination facilitates apoptosis through both Akt signaling inhibition and upregulation of ER stress-induced, GADD153-mediated pathways. For example, ectopic expression of constitutively active Akt significantly attenuated the inhibitory effect on cell survival, and siRNA-mediated knockdown of GADD153 protected cells from undergoing apoptosis in response to drug co-treatments. Furthermore, the OSU-03012/EGFR inhibitor combination induced GADD153-mediated upregulation of death receptor 5 expression and subsequent activation of the extrinsic apoptosis pathway. It is noteworthy that the ER stress response induced by this combination was atypical in that the cytoprotective pathway was not engaged. In addition, in vivo suppression of tumor growth and modulation of intratumoral biomarkers were observed in a H1155 tumor xenograft model in nude mice. These data suggest that the concomitant modulation of Akt and ER stress pathways with the OSU-03012/EGFR inhibitor combination represents a unique approach to overcoming EGFR inhibitor resistance in NSCLC and perhaps other types of cancer with elevated basal Akt activities. In addition to the OSU-03012/EGFR inhibitor combinations, erlotinib in combination with HDAC inhibitor vorinostat or OSU-HDAC42 exhibits significantly enhanced anticancer activity in two EGFR-inhibitor resistant NSCLC cell lines, H1299 and H1975, by targeting signaling involved in regulation of cell survival and death at multiple levels. The erlotinib/HDAC inhibitor combination elicited massive apoptosis in both of H1299 and H1975 cell lines, suggesting that the anticancer activity of this combination strategy is independent of p53 function and EGFR mutations. Evidence indicates that this combination facilitates apoptosis through inhibition of Akt and Erk survival signaling and activation of NR4A1-mediated apoptosis. The studies presented here provide novel mechanistic rationales for the clinical use of EGFR inhibitors to possibly form more effective protocols for treating NSCLC patients.

IASLC Thoracic Oncology E Book

IASLC Thoracic Oncology E Book Book
Author : Harvey Pass,David Ball,Giorgio Scagliotti
Publisher : Elsevier Health Sciences
Release : 2017-04-21
ISBN : 0323527841
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Global experts, in conjunction with the International Association for the Study of Lung Cancer, bring you up to date with today’s best approaches to lung cancer diagnosis, treatment, and follow-up. IASLC Thoracic Oncology, 2nd Edition, keeps you abreast of the entire scope of this fast-changing field, from epidemiology to diagnosis to treatment to advocacy. Written in a straightforward, practical style for the busy clinician, this comprehensive, multidisciplinary title is a must-have for anyone involved in the care of patients with lung cancer and other thoracic malignancies. Offers practical, relevant coverage of basic science, epidemiology, pulmonology, medical and radiation oncology, surgery, pathology, palliative care, nursing, and advocacy. Provides authoritative guidance from the IASLC – the only global organization dedicated to the study of lung cancer. Includes new content on molecular testing, immunotherapy, early detection, staging and the IASLC staging system, surgical resection for stage I and stage II lung cancer, and stem cells in lung cancer. Features a new full-color design throughout, as well as updated diagnostic algorithms.

Lung Cancer

Lung Cancer Book
Author : Anne C. Chiang,Roy Herbst
Publisher : Springer Nature
Release : 2021
ISBN : 3030740285
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.

Protein Kinase Inhibitors

Protein Kinase Inhibitors Book
Author : Md. Imtaiyaz Hassan,Saba Noor
Publisher : Academic Press
Release : 2022-05-19
ISBN : 0323913490
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Protein Kinase Inhibitors: From Discovery to Therapeutics offers a foundational, pragmatic overview of protein kinases inhibitors and their potential role in disease modulation and treatment. Here, international experts in the field offer an integrated discussion of kinase inhibitor biology, biomarker discovery, and methods for drug design and development. After a brief overview of kinases and kinase inhibitors, subsequent chapters discuss individual kinases that are representative of the wider kinases and kinase families, including their roles in disease pathogenesis, underlying mechanisms, potential inhibitors and their modes of action for therapeutic modulation. Several potential drugs under different stages of clinical trials are discussed, including their relevance to cancer, diabetes, obesity, cardiovascular, neurological, and auto-immune and inflammatory disease, among other disorders. The book also addresses the challenges and opportunities for future kinase inhibitor development. Provides a thorough overview of kinase inhibitor biology and its role in disease progression and modulation Examines protein kinase inhibitor drugs in various stages of clinical trials and development Offers methods and protocols for protein kinase inhibitor research studies and drug design and development Includes chapter contributions from international leaders in the field